Matko Kalac

778 total citations
37 papers, 423 citations indexed

About

Matko Kalac is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Matko Kalac has authored 37 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Oncology and 9 papers in Immunology. Recurrent topics in Matko Kalac's work include Histone Deacetylase Inhibitors Research (9 papers), T-cell and Retrovirus Studies (7 papers) and Prostate Cancer Treatment and Research (7 papers). Matko Kalac is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), T-cell and Retrovirus Studies (7 papers) and Prostate Cancer Treatment and Research (7 papers). Matko Kalac collaborates with scholars based in United States, Australia and Italy. Matko Kalac's co-authors include Owen A. O’Connor, Enrica Marchi, Jennifer E. Amengual, Luigi Scotto, Govind Bhagat, Samir Parekh, Violetta V. Leshchenko, Benjamin Tycko, Netha Ulahannan and Alexis M. Temkin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Matko Kalac

34 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matko Kalac United States 9 220 161 148 89 53 37 423
Danielle Shafer United States 12 169 0.8× 85 0.5× 151 1.0× 48 0.5× 31 0.6× 30 398
Ellen Neylon United States 12 156 0.7× 371 2.3× 227 1.5× 167 1.9× 144 2.7× 27 571
Minami Yamada Japan 12 77 0.3× 90 0.6× 134 0.9× 104 1.2× 48 0.9× 24 369
Antonia Rodríguez Spain 10 269 1.2× 284 1.8× 179 1.2× 99 1.1× 24 0.5× 14 595
Yaozhong Zhao China 10 184 0.8× 110 0.7× 149 1.0× 83 0.9× 6 0.1× 47 410
Bouchra Ghazi Morocco 6 96 0.4× 205 1.3× 176 1.2× 175 2.0× 38 0.7× 22 361
M Wasik Poland 5 109 0.5× 114 0.7× 181 1.2× 165 1.9× 78 1.5× 11 341
Cristina Quero Spain 10 175 0.8× 115 0.7× 133 0.9× 43 0.5× 19 0.4× 19 367
Hong Yi Wang United States 7 175 0.8× 205 1.3× 531 3.6× 383 4.3× 69 1.3× 12 791
Harald Biersack Germany 13 219 1.0× 116 0.7× 242 1.6× 71 0.8× 8 0.2× 33 560

Countries citing papers authored by Matko Kalac

Since Specialization
Citations

This map shows the geographic impact of Matko Kalac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matko Kalac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matko Kalac more than expected).

Fields of papers citing papers by Matko Kalac

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matko Kalac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matko Kalac. The network helps show where Matko Kalac may publish in the future.

Co-authorship network of co-authors of Matko Kalac

This figure shows the co-authorship network connecting the top 25 collaborators of Matko Kalac. A scholar is included among the top collaborators of Matko Kalac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matko Kalac. Matko Kalac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Armstrong, Andrew J., Daniel P. Petrylak, Neal D. Shore, et al.. (2025). ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology. 43(16_suppl). 5005–5005. 3 indexed citations
4.
Shore, Neal D., Murilo Luz, Ugo De Giorgi, et al.. (2025). Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 394(6). 563–575. 1 indexed citations
5.
6.
7.
Ciccolini, Kathryn, et al.. (2023). CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma. Cureus. 15(9). e44542–e44542. 1 indexed citations
8.
Kalac, Matko, Constantine S. Tam, Mendel Goldfinger, et al.. (2021). A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma. Blood. 138(Supplement 1). 4550–4550. 1 indexed citations
9.
Xu, Xin, Matko Kalac, Joshua Brody, et al.. (2020). Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). Cell Death and Disease. 11(2). 94–94. 20 indexed citations
10.
Kalac, Matko, Shi‐Xian Deng, Luigi Scotto, et al.. (2020). N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB. iScience. 23(12). 101884–101884.
11.
Amengual, Jennifer E., Jennifer Kimberly Lue, Ahmed Sawas, et al.. (2017). A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 131(4). 397–407. 91 indexed citations
12.
Marron, Thomas U., Matko Kalac, & Joshua Brody. (2017). An Update on the Use of Immunotherapy in the Treatment of Lymphoma. Current Hematologic Malignancy Reports. 12(4). 282–289. 2 indexed citations
13.
Scotto, Luigi, Marianna Kruithof‐de Julio, Luca Paoluzzi, et al.. (2012). Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas. Clinical Cancer Research. 18(14). 3803–3811. 10 indexed citations
14.
Marchi, Enrica, Matko Kalac, Christine McIntosh, et al.. (2011). Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma. Blood. 118(21). 2727–2727. 3 indexed citations
15.
Amengual, Jennifer E., Matko Kalac, Luigi Scotto, et al.. (2011). Therapeutic Targeting of the Bcl-6: p53 Axis with Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma,. Blood. 118(21). 3733–3733. 1 indexed citations
16.
17.
18.
Paoluzzi, Luca, Yukiko Kitagawa, Matko Kalac, Jasmine Zain, & Owen A. O’Connor. (2008). New Drugs for the Treatment of Lymphoma. Hematology/Oncology Clinics of North America. 22(5). 1007–1035. 7 indexed citations
19.
Kalac, Matko, Alfonso Quintás-Cardama, Radovan Vrḫovac, Hagop M. Kantarjian, & Srđan Verstovšek. (2007). A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer. 110(5). 955–964. 22 indexed citations
20.
Kalac, Matko, et al.. (2007). Central Nervous System Involvement of Previously Undiagnosed Chronic Lymphocytic Leukemia in a Patient with Neuroborreliosis. International Journal of Hematology. 85(4). 323–325. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danielle Shafer Breakdown of academic impact, for papers by Ellen Neylon Breakdown of academic impact, for papers by Minami Yamada Breakdown of academic impact, for papers by Antonia Rodríguez Breakdown of academic impact, for papers by Yaozhong Zhao Breakdown of academic impact, for papers by Bouchra Ghazi Breakdown of academic impact, for papers by M Wasik Breakdown of academic impact, for papers by Cristina Quero Breakdown of academic impact, for papers by Hong Yi Wang Breakdown of academic impact, for papers by Harald Biersack
Rankless by CCL
2026